Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 plus dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis
NL-OMON50586Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixazomib and dexamethasone in light-chain amyloidosis (2 arms), sponsored by Takeda. Primary endpoint: Safety profile of MLN9708 and/or other study medication. Started Jan 2013; status: active, not recruiting.
02
Drugs
ixazomibdexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON50586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50586.